227 related articles for article (PubMed ID: 23567304)
21. Plasma leptin and adiponectin in COPD exacerbations: associations with inflammatory biomarkers.
Krommidas G; Kostikas K; Papatheodorou G; Koutsokera A; Gourgoulianis KI; Roussos C; Koulouris NG; Loukides S
Respir Med; 2010 Jan; 104(1):40-6. PubMed ID: 19782551
[TBL] [Abstract][Full Text] [Related]
22. Circulating visfatin in chronic obstructive pulmonary disease.
Liu X; Ji Y; Chen J; Li S; Luo F
Nutrition; 2009 Apr; 25(4):373-8. PubMed ID: 19056239
[TBL] [Abstract][Full Text] [Related]
23. [Etiology and biomarkers of systemic inflammation in mild to moderate COPD exacerbations].
Saldías PF; Díaz PO; Dreyse DJ; Gaggero BA; Sandoval AC; Lisboa BC
Rev Med Chil; 2012 Jan; 140(1):10-8. PubMed ID: 22552550
[TBL] [Abstract][Full Text] [Related]
24. Platelet count, mean platelet volume and smoking status in stable chronic obstructive pulmonary disease.
Biljak VR; Pancirov D; Cepelak I; Popović-Grle S; Stjepanović G; Grubišić TŽ
Platelets; 2011; 22(6):466-70. PubMed ID: 21506665
[TBL] [Abstract][Full Text] [Related]
25. [C-Reactive protein levels in patients with chronic obstructive pulmonary disease].
Díaz O; Parada A; Ramos C; Klaassen J; Díaz JC; Andresen M; Lisboa C; Saldías F
Rev Med Chil; 2012 May; 140(5):569-78. PubMed ID: 23096661
[TBL] [Abstract][Full Text] [Related]
26. Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease.
Valipour A; Schreder M; Wolzt M; Saliba S; Kapiotis S; Eickhoff P; Burghuber OC
Clin Sci (Lond); 2008 Oct; 115(7):225-32. PubMed ID: 18307413
[TBL] [Abstract][Full Text] [Related]
27. Skin condition and its relationship to systemic inflammation in chronic obstructive pulmonary disease.
Majewski S; Pietrzak A; Tworek D; Szewczyk K; Kumor-Kisielewska A; Kurmanowska Z; Górski P; Zalewska-Janowska A; Piotrowski WJ
Int J Chron Obstruct Pulmon Dis; 2017; 12():2407-2415. PubMed ID: 28860735
[TBL] [Abstract][Full Text] [Related]
28. Biomarkers of systemic inflammation in stable and exacerbation phases of COPD.
Karadag F; Karul AB; Cildag O; Yilmaz M; Ozcan H
Lung; 2008; 186(6):403-9. PubMed ID: 18807087
[TBL] [Abstract][Full Text] [Related]
29. Systemic inflammation and systemic oxidative stress in patients with acute exacerbations of COPD.
Tkacova R; Kluchova Z; Joppa P; Petrasova D; Molcanyiova A
Respir Med; 2007 Aug; 101(8):1670-6. PubMed ID: 17449234
[TBL] [Abstract][Full Text] [Related]
30. Serum myostatin levels and skeletal muscle wasting in chronic obstructive pulmonary disease.
Ju CR; Chen RC
Respir Med; 2012 Jan; 106(1):102-8. PubMed ID: 21840694
[TBL] [Abstract][Full Text] [Related]
31. Echocardiographic Evaluation of the Relationship Between inflammatory factors (IL6, TNFα, hs-CRP) and Secondary Pulmonary Hypertension in patients with COPD. A Cross sectional study.
Ansarin K; Rashidi F; Namdar H; Ghaffari M; Sharifi A
Pneumologia; 2015; 64(3):31-5. PubMed ID: 26738368
[TBL] [Abstract][Full Text] [Related]
32. High levels of interleukin-6 and 8-iso-prostaglandin in the exhaled breath condensate and serum of patients with chronic obstructive pulmonary disease related pulmonary hypertension.
He H; Tao Y; Chen X; Qiu H; Zhu J; Zhang J; Ma H
Chin Med J (Engl); 2014; 127(9):1608-12. PubMed ID: 24791862
[TBL] [Abstract][Full Text] [Related]
33. Comparison of inflammation biomarkers among chronic obstructive pulmonary disease groups: A cross sectional study.
Yazici O; Gulen ST; Yenisey C; Eryilmaz U; Abas BI; Polatli M
Niger J Clin Pract; 2020 Jun; 23(6):817-824. PubMed ID: 32525117
[TBL] [Abstract][Full Text] [Related]
34. Ischemia-modified albumin (IMA) is increased in patients with chronic hepatitis C infection and related to markers of oxidative stress and inflammation.
Zuwała-Jagiełło J; Warwas M; Pazgan-Simon M
Acta Biochim Pol; 2012; 59(4):661-7. PubMed ID: 23227456
[TBL] [Abstract][Full Text] [Related]
35. Systemic inflammation, COPD, and pulmonary hypertension.
Hoeper MM; Welte T
Chest; 2007 Feb; 131(2):634-5; author reply 635. PubMed ID: 17296674
[No Abstract] [Full Text] [Related]
36. Markers of disease severity in chronic obstructive pulmonary disease.
Franciosi LG; Page CP; Celli BR; Cazzola M; Walker MJ; Danhof M; Rabe KF; Della Pasqua OE
Pulm Pharmacol Ther; 2006; 19(3):189-99. PubMed ID: 16019244
[TBL] [Abstract][Full Text] [Related]
37. The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data.
Basyigit I; Yildiz F; Ozkara SK; Yildirim E; Boyaci H; Ilgazli A
Ann Pharmacother; 2004 Sep; 38(9):1400-5. PubMed ID: 15252191
[TBL] [Abstract][Full Text] [Related]
38. Alterations in acetylcholinesterase and butyrylcholinesterase activities in chronic obstructive pulmonary disease: relationships with oxidative and inflammatory markers.
Ben Anes A; Ben Nasr H; Garrouch A; Bennour S; Bchir S; Hachana M; Benzarti M; Tabka Z; Chahed K
Mol Cell Biochem; 2018 Aug; 445(1-2):1-11. PubMed ID: 29234928
[TBL] [Abstract][Full Text] [Related]
39. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease.
Vanfleteren LE; Spruit MA; Groenen M; Gaffron S; van Empel VP; Bruijnzeel PL; Rutten EP; Op 't Roodt J; Wouters EF; Franssen FM
Am J Respir Crit Care Med; 2013 Apr; 187(7):728-35. PubMed ID: 23392440
[TBL] [Abstract][Full Text] [Related]
40. Increased expression of interleukin-18 and its receptor in peripheral blood of patients with chronic obstructive pulmonary disease.
Wang J; Liu X; Xie M; Xie J; Xiong W; Xu Y
COPD; 2012 Aug; 9(4):375-81. PubMed ID: 22489883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
